Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) - PubMed (original) (raw)
Practice Guideline
. 2007 Sep;132(3 Suppl):324S-339S.
doi: 10.1378/chest.07-1385.
Affiliations
- PMID: 17873178
- DOI: 10.1378/chest.07-1385
Practice Guideline
Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)
George R Simon et al. Chest. 2007 Sep.
Abstract
Purposes: This guideline is for the management of patients with small cell lung cancer (SCLC) and is based on currently available information. As part of the guideline, an evidence-based review of the literature was commissioned that enables the reader to assess the evidence as we have attempted to put the clinical implications into perspective.
Methods: We conducted a comprehensive review of the available literature and the previous American College of Chest Physicians guidelines of SCLC. Controversial and less understood areas of the management of SCLC were then subject to an exhaustive review of the literature and detail analyses. Experts in evidence-based analyses compiled the accompanying systematic review titled "Evidence for Management of SCLC." The evidence was then assessed by a panel of experts to incorporate "clinical relevance." The resultant guidelines were then scored according to the grading system outlined by the American College of Chest Physicians grading system task force.
Results: SCLC accounts for 13 to 20% of all lung cancers. Highly smoking related and initially responsive to treatment, it leads to death rapidly in 2 to 4 months without treatment. SCLC is staged as limited-stage and extensive-stage disease. Limited-stage disease is treated with curative intent with chemotherapy and radiation therapy, with approximately 20% of patients achieving a cure. For all patients with limited-stage disease, median survival is 16 to 22 months. Extensive-stage disease is primarily treated with chemotherapy with a high initial response rate of 60 to 70% but with a median survival of 10 months. All patients achieving a complete remission should be offered prophylactic cranial irradiation. Relapsed or refractory SCLC has a uniformly poor prognosis.
Conclusion: In this section, evidence-based guidelines for the staging and treatment of SCLC are outlined. Limited-stage SCLC is treated with curative intent. Extensive-stage SCLC has high initial responses to chemotherapy but with an ultimately dismal prognosis with few survivors beyond 2 years.
Similar articles
- Small cell lung cancer.
Simon GR, Wagner H; American College of Chest Physicians. Simon GR, et al. Chest. 2003 Jan;123(1 Suppl):259S-271S. doi: 10.1378/chest.123.1_suppl.259s. Chest. 2003. PMID: 12527584 Review. - Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).
Samson DJ, Seidenfeld J, Simon GR, Turrisi AT 3rd, Bonnell C, Ziegler KM, Aronson N; American College of Chest Physicians. Samson DJ, et al. Chest. 2007 Sep;132(3 Suppl):314S-323S. doi: 10.1378/chest.07-1384. Chest. 2007. PMID: 17873177 Review. - Treatment of small cell lung cancer.
Kurup A, Hanna NH. Kurup A, et al. Crit Rev Oncol Hematol. 2004 Nov;52(2):117-26. doi: 10.1016/j.critrevonc.2004.08.005. Crit Rev Oncol Hematol. 2004. PMID: 15501076 Review. - Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.
Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K, Pietanza MC, Ramalingam SS, Turrisi AT 3rd, Giaccone G. Rudin CM, et al. J Clin Oncol. 2015 Dec 1;33(34):4106-11. doi: 10.1200/JCO.2015.63.7918. Epub 2015 Sep 8. J Clin Oncol. 2015. PMID: 26351333
Cited by
- Lung cancer in middle and southern Morocco.
Tafenzi HA, Choulli F, Baladi A, Essaadi I, Belbaraka R. Tafenzi HA, et al. Ecancermedicalscience. 2023 Mar 13;17:1518. doi: 10.3332/ecancer.2023.1518. eCollection 2023. Ecancermedicalscience. 2023. PMID: 37113715 Free PMC article. - MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Chen J, Guanizo AC, Jakasekara WSN, Inampudi C, Luong Q, Garama DJ, Alamgeer M, Thakur N, DeVeer M, Ganju V, Watkins DN, Cain JE, Gough DJ. Chen J, et al. J Exp Clin Cancer Res. 2023 Apr 26;42(1):100. doi: 10.1186/s13046-023-02678-1. J Exp Clin Cancer Res. 2023. PMID: 37098540 Free PMC article. - Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Hanvesakul R, Rengarajan B, Naveh N, Boccuti A, Park JE, Adeyemi A, Caisip C, Jansen JP, Wilson FR. Hanvesakul R, et al. J Comp Eff Res. 2023 May;12(5):e220098. doi: 10.57264/cer-2022-0098. Epub 2023 Apr 20. J Comp Eff Res. 2023. PMID: 37079341 Free PMC article. - Lung cancer immunotherapy: progress, pitfalls, and promises.
Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lahiri A, et al. Mol Cancer. 2023 Feb 21;22(1):40. doi: 10.1186/s12943-023-01740-y. Mol Cancer. 2023. PMID: 36810079 Free PMC article. Review. - Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.
Liu Q, Xu JY, Xu YH, Chen M, Deng LC, Wu JP, Zhou T, Zhang LQ, Tan J, Pu XX, Shang YL, Hua J, Li YQ, Cai W, Gu YL, Peng XC, Chan PC, Jabbour SK, Nam HS, Hua D. Liu Q, et al. Transl Lung Cancer Res. 2022 May;11(5):832-844. doi: 10.21037/tlcr-22-313. Transl Lung Cancer Res. 2022. PMID: 35693282 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials